JPMorgan keeps GSK stock Underweight at GBp 1,700.00 target

Published on 10/13/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter turnover rose 5.00 percent to GBP 8.41 billion. GSK stock costs EUR 21.08 on October 13, 2026 at 2:16 p.m. CEST.

Array

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

JPMorgan maintained its Underweight rating on GSK with a GBp 1,700.00 price target in a note dated October 1, 2026, according to finanzen.at. GSK stock was trading at EUR 21.08 at Lang & Schwarz on October 13, 2026 at 2:16 p.m. CEST.

JPMorgan keeps a cautious view

The JPMorgan note kept the Underweight assessment and cited a third-quarter outlook in which cost management was expected to support performance. The target of GBp 1,700.00 was stated in the same report, while the rating remained Underweight.

The target is in the home-market pence quotation, whereas the live market reference here is the euro price at Lang & Schwarz. That currency distinction prevents a direct percentage comparison between the target and the euro quote.

Second-quarter growth reached 5.00 percent

GSK's second-quarter 2026 turnover rose 5.00 percent at constant exchange rates to GBP 8.41 billion, while core operating profit increased 7.00 percent to GBP 2.80 billion, according to Drillr. The core operating margin was 33.30 percent in that period.

The mix was uneven: HIV sales rose 10.00 percent to GBP 2.08 billion, while general medicines declined 9.00 percent to GBP 2.34 billion in the second quarter. This split makes specialty medicines and vaccines central to the next earnings update.

Results are scheduled for October 28

GSK is scheduled to publish its third-quarter 2026 results on October 28, 2026, covering the period ended September 30, 2026, according to finanzen.net. The same preview cited consensus expectations of GBP 8.88 billion in revenue and GBP 0.505 in earnings per share.

Comparison with peers

GSK: P/E 14.95, market capitalization USD 94.0 billion.

AstraZeneca (Nasdaq, USD): P/E 24.10, market capitalization USD 245.5 billion.

Novartis (NYSE, USD): P/E 22.17, market capitalization USD 273.4 billion.

Stock position and trading price

GSK's euro quote of EUR 21.08 at Lang & Schwarz on October 13, 2026 at 2:16 p.m. CEST sits within the dated EUR 18.40 to EUR 26.04 52-week range shown for the German quotation on October 12, 2026. The market capitalization for that quotation was EUR 102.4 billion on October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.